

**Supplementary Table 2.** Comparisons of clinicopathological characteristics between different stroma types (n=359)

Characteristics		Dormant (n=74)	Fibrogenic (n=105)	Inert (n=105)	Fibrolytic (n=75)	Total (%)	$\chi^2$	P-value
Age, year	≤50	13 (17.6%)	19 (18.1%)	25 (23.8%)	17 (22.7%)	74 (20.6)	1.68	0.643
	>50	61 (82.4%)	86 (81.9%)	80 (76.2%)	58 (77.3%)	284 (79.4)		
Gender	Female	35 (47.3%)	43 (41.0%)	45 (42.9%)	30 (40.0%)	153 (42.6)	0.99	0.803
	Male	39 (52.7%)	62 (59.0%)	60 (57.1%)	45 (60.0%)	206 (57.4)		
HBsAg	Negative	53 (71.6%)	77 (73.3%)	70 (66.7%)	52 (69.3%)	252 (70.2)	1.22	0.749
	Positive	21 (28.4%)	28 (26.7%)	35 (33.3%)	23 (30.7%)	107 (29.8)		
AFP, ng/mL	≤20	66 (89.2%)	95 (90.5%)	90 (85.7%)	66 (88.0%)	317 (88.3)	1.22	0.747
	>20	8 (10.8%)	10 (9.5%)	15 (14.3%)	9 (12.0%)	42 (11.7)		
CA19-9, U/L	≤36	33 (44.6%)	37 (35.2%)	43 (41.0%)	36 (48.0%)	149 (41.5)	3.31	0.347
	>36	41 (55.4%)	68 (64.8%)	62 (59.0%)	39 (52.0%)	210 (58.5)		
GGT, U/L	≤36	39 (52.7%)	46 (43.8%)	58 (55.2%)	29 (38.7%)	172(47.9)	6.22	0.102
	>36	35 (47.3%)	59 (56.2%)	47 (44.8%)	46 (61.3%)	187(52.1)		
Liver cirrhosis	No	62 (83.8%)	80 (76.2%)	72 (68.6%)	59 (78.7%)	273 (76.0)	5.94	0.115
	Yes	12 (16.2%)	25 (23.8%)	33 (31.4%)	16 (21.3%)	86 (24.0)		
Tumor size, cm	≤5	39 (52.7%)	53 (50.5%)	43 (41.0%)	24 (32.0%)	159 (44.3)	8.82	0.032
	>5	35 (47.3%)	52 (49.5%)	62 (59.0%)	51 (68.0%)	200 (55.7)		
Tumor number	Single	58 (78.4%)	83 (79.0%)	71 (67.6%)	46 (61.3%)	258 (71.9)	9.28	0.026
	Multiple	16 (21.6%)	22 (21.0%)	34 (32.4%)	29 (38.7%)	101 (28.1)		
LVI	No	60 (81.1%)	86 (81.9%)	78 (74.3%)	58 (77.3%)	282 (78.6)	2.18	0.536
	Yes	14 (18.9%)	19 (18.1%)	27 (25.7%)	17 (22.7%)	77 (21.4)		
Lymphatic metastasis	No	66 (89.2%)	89 (84.8%)	91 (86.7%)	60 (80.0%)	306 (85.2)	2.74	0.433
	Yes	8 (10.8%)	16 (15.2%)	14 (13.3%)	15 (20.0%)	53 (14.8)		
Tumor encapsulation	Complete	14 (18.9%)	17 (16.2%)	22 (21.0%)	9 (12.0%)	62 (17.3)	2.68	0.444
	None	60 (81.1%)	88 (83.8%)	83 (79.0%)	66 (88.0%)	297 (82.7)		
Tumor differentiation	I+II	44 (59.5%)	54 (51.4%)	54 (51.4%)	29 (38.7%)	181 (50.4)	6.65	0.084
	III+IV	30 (40.5%)	51 (48.6%)	51 (48.6%)	46 (61.3%)	178 (49.6)		
TNM stage	I	44 (59.5%)	56 (53.3%)	51 (48.6%)	31 (41.3%)	182 (50.7)	5.39	0.146
	II+III+IV	30 (40.5%)	49 (46.7%)	54 (51.4%)	44 (58.7%)	177 (49.3)		

AFP, alpha-fetoprotein; GGT, gamma glutamyl transferase; CA 19-9, carbohydrate antigen 19-9; LVI, lymphatic vascular invasion; TNM, tumor-node-metastasis.